Current Hematologic Malignancy Reports

, Volume 10, Issue 3, pp 266–271 | Cite as

Treating Burkitt Lymphoma in Adults

  • Carla CasuloEmail author
  • Jonathan Friedberg
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)
Part of the following topical collections:
  1. Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma


Burkitt lymphoma is an uncommon form of aggressive lymphoma affecting approximately 1200 patients per year in the USA. It is characterized by a translocation involving the MYC oncogene. Three subtypes of Burkitt lymphoma are recognized: the endemic form, occurring primarily in Africa and associated with the Epstein-Barr virus (EBV); the sporadic form, representing less than 3 % of all non-Hodgkin lymphomas (NHL); and the immunodeficiency-associated form, occurring primarily in HIV-infected patients. Burkitt lymphoma appears histologically with a diffuse pattern of intermediate-sized monomorphic B cells, multiple nucleoli, a very high proliferative rate, and frequent mitotic figures. Recent advances in transcriptional profiling have improved the current molecular understanding of Burkitt lymphoma and have better characterized its mutational landscape. Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease.


Burkitt lymphoma Non-Hodgkin lymphomas MYC oncogene Hodgkin lymphoma 


Compliance with Ethics Guidelines

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    O’Conor GT, Davies JN. Malignant tumors in African children. With special reference to malignant lymphoma. J Pediatr. 1960;56:526–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1:702–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci. 2007;7:166–75.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012;156:744–56.CrossRefPubMedGoogle Scholar
  5. 5.
    de-The G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature. 1978;274:756–61.Google Scholar
  6. 6.
    Geser A, Brubaker G, Draper CC. Effect of a malaria suppression program on the incidence of African Burkitt’s lymphoma. Am J Epidemiol. 1989;129:740–52.PubMedGoogle Scholar
  7. 7.
    Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca KA, Thorley-Lawson DA. A multifactorial role for P. falciparum malaria in endemic Burkitt’s lymphoma pathogenesis. PLoS Path. 2014;10:e1004170.Google Scholar
  8. 8.
    Kalter SP, Riggs SA, Cabanillas F, et al. Aggressive non-Hodgkin’s lymphomas in immunocompromised homosexual males. Blood. 1985;66:655–9.PubMedGoogle Scholar
  9. 9.
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–76.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973–2005. Int J Canc J Int Canc. 2010;126:1732–9.Google Scholar
  11. 11.
    Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321–5.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316–20.CrossRefPubMedGoogle Scholar
  15. 15.•
    Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–20. This paper highlights novel methods of high throughput sequencing to reveal novel mutations contributing to BL pathogenesis” suggesting opportunities to improve therapy for patients with BL. PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Nakamura N, Nakamine H, Tamaru J, et al. The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Modern Pathol Offic J United States Can Acad Pathol Inc. 2002;15:771–6.CrossRefGoogle Scholar
  17. 17.
    Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Offic J Am Soc Clin Oncol. 2014;32:3059–68.CrossRefGoogle Scholar
  18. 18.
    Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol Offic J Am Soc Clin Oncol. 1996;14:925–34.Google Scholar
  19. 19.
    Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100:1438–48.CrossRefPubMedGoogle Scholar
  20. 20.
    Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85:664–74.PubMedGoogle Scholar
  21. 21.
    Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 Study. Annal Oncol Offic J Eur Soc Med Oncol / ESMO. 2002;13:1264–74.CrossRefGoogle Scholar
  22. 22.
    Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112:2248–60.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22:1859–64.CrossRefPubMedGoogle Scholar
  24. 24.
    Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol. 2012;156:234–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Evens AM, Carson KR, Kolesar J, et al. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol. 2013;24:3076–81.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.••
    Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–25. This very important paper demonstrates that with lower intensity infusional chemotherapy, patients with BL have excellent outcomes with manageable toxicity. This paper also deals with CNS prophylaxis as well as addressing CNS involvement of BL patients. PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol Offic J Am Soc Clin Oncol. 1999;17:2461–70.Google Scholar
  28. 28.
    Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–80.CrossRefPubMedGoogle Scholar
  29. 29.•
    Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B Study 10 002. Br J Haematol. 2014;165:102–11. This large study demonstrated that a brief but highly intense chemotherapy program is feasible and effective in a multicenter setting. PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol Offic J Am Soc Clin Oncol. 1996;14:2465–72.Google Scholar
  31. 31.
    Song KW, Barnett MJ, Gascoyne RD, et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol. 2006;133:634–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Hoffmann C, Wolf E, Wyen C, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006;47:1872–80.CrossRefPubMedGoogle Scholar
  33. 33.
    Ribera JM, Garcia O, Grande C, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119:1660–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009;9:307–10.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 2014;33:2928–37.CrossRefPubMedGoogle Scholar
  36. 36.
    Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108:16669–74.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Tan Y, Sementino E, Pei J, Kadariya Y, Ito TK, Testa JR. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer Biol Ther. 2015;16(4):580-8. doi:  10.1080/15384047.2015.1018495.

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Wilmot Cancer InstituteUniversity of RochesterRochesterUSA

Personalised recommendations